LENZ Stock Analysis: LENZ Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 183m USD | 12M Return: -87.7% | US52635N1037 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.39M
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
LENZ Therapeutics, Inc. is a US-based commercial pharmaceutical company headquartered in Solana Beach, California, focused on developing and commercializing therapies to improve vision. Its lead product candidates, VIZZ and LNZ101, target presbyopia, an age-related loss of near-vision typically affecting adults over 40. The company was founded in 2013 and previously operated as Presbyopia Therapies, Inc. before adopting its current name in June 2021.
The company trades on NASDAQ under the ticker LENZ, having completed its IPO on June 25, 2021. It is classified within the Health Care sector and the Biotechnology sub-industry, a segment that typically relies on clinical trial outcomes and regulatory approvals to drive long-term value. With a micro-cap market capitalization of approximately $199M USD, LENZ represents a smaller, development-stage-oriented player in the ophthalmology pharmaceuticals space.
- VIZZ FDA approval enables U.S. commercial launch
- Cash burn may force dilutive equity raise
- Vuity competition and pipeline entrants challenge market share
| Net Income: -126.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.48 > 0.02 and ΔFCF/TA -26.32 > 1.0 |
| NWC/Revenue: 1.01k% < 20% (prev 4.01k%; Δ -3.00k% < -1%) |
| CFO/TA -0.48 > 3% & CFO -113.9m > Net Income -126.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 13.55 > 1.5 & < 3 |
| Outstanding Shares: last quarter (31.4m) vs 12m ago 11.74% < -2% |
| Gross Margin: 90.14% > 18% (prev 98.07%; Δ -7.92% > 0.5%) |
| Asset Turnover: 9.46% > 50% (prev 2.33%; Δ 7.13% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.91 (Total Current Assets 233.3m - Total Current Liabilities 17.2m) / Total Assets 236.6m |
| B: -1.27 (Retained Earnings -300.5m / Total Assets 236.6m) |
| C: -0.56 (EBIT TTM -126.0m / Avg Total Assets 227.0m) |
| D: 12.65 (Book Value of Equity 219.3m / Total Liabilities 17.3m) |
| Altman-Z'' = 11.40 = AAA |
As of September 10, 2026, the stock is trading at USD 4.91 with a total of 702,173 shares traded. Over the past week, the price has changed by -6.12%, over one month by -8.40%, over three months by -27.69% and over the past year by -87.69%.
Current recommended Stop Loss: 4.30 (which is 12.4% or 1.6 ATR below the current price).
LENZ Therapeutics has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy LENZ.
- StrongBuy: 5
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 24 | 388.8% |
P/S = 8.5299
P/B = 0.7487
Revenue TTM = 21.5m USD
EBIT TTM = -126.0m USD
EBITDA TTM = -125.5m USD
Long Term Debt = unknown (none)
Short Term Debt = 465k USD (from shortTermDebt, last fiscal year)
Debt = 795k USD (from shortLongTermDebtTotal, last quarter) + Leases 673k
Net Debt = -219.2m USD (calculated: Debt 795k - CCE 220.0m)
Enterprise Value = 183.2m USD (floored to Market Cap, CCE > MCap+Debt)
Interest Coverage Ratio = unknown (Ebit TTM -126.0m / Interest Expense TTM 0.0)
EV/FCF = -1.60x (Enterprise Value 183.2m / FCF TTM -114.4m)
FCF Yield = -62.46% (FCF TTM -114.4m / Enterprise Value 183.2m)
FCF Margin = -532.8% (FCF TTM -114.4m / Revenue TTM 21.5m)
Net Margin = -586.7% (Net Income TTM -126.0m / Revenue TTM 21.5m)
Gross Margin = 90.14% ((Revenue TTM 21.5m - Cost of Revenue TTM 2.12m) / Revenue TTM)
Gross Margin QoQ = 94.90% (prev 37.56%)
Tobins Q-Ratio = 0.77 (Enterprise Value 183.2m / Total Assets 236.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 795k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -99.5m (EBIT -126.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 13.55 (Total Current Assets 233.3m / Total Current Liabilities 17.2m)
Debt / Equity = 0.00 (Debt 795k / totalStockholderEquity, last quarter 219.3m)
Debt / EBITDA = 1.75 (negative EBITDA) (Net Debt -219.2m / EBITDA -125.5m)
Debt / FCF = 1.92 (negative FCF - burning cash) (Net Debt -219.2m / FCF TTM -114.4m)
Total Stockholder Equity = 236.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -55.52% (Net Income -126.0m / Total Assets 236.6m)
RoE = -53.39% (Net Income TTM -126.0m / Total Stockholder Equity 236.0m)
RoCE = -57.43% (EBIT -126.0m / Capital Employed (Total Assets 236.6m - Current Liab 17.2m))
RoIC = -45.50% (negative operating profit) (NOPAT -99.5m / Invested Capital 218.8m)
WACC = 11.59% (E(183.2m)/V(184.0m) * Re(11.64%) + D(795k)/V(184.0m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.64% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 71.05 | Cagr: 132.1%
[DCF] Fair Price = unknown (Cash Flow -114.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.04 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 1.04 | # QB: 1
EPS current Quarter (2026-09-30): EPS=-1.07 | Chg30d=-0.53% | Revisions=-40% | Analysts=7
EPS current Year (2026-12-31): EPS=-4.25 | Chg30d=+7.13% | Revisions=-17% | GrowthEPS=-48.9% | GrowthRev=-11.0%
EPS next Year (2027-12-31): EPS=-3.08 | Chg30d=+12.32% | Revisions=-38% | GrowthEPS=+27.6% | GrowthRev=+153.0%
[Analyst] Revisions Ratio: -46% (up=2, down=8)